OrthoPediatrics (NASDAQ:KIDS) PT Lowered to $28.00 at Truist Financial

OrthoPediatrics (NASDAQ:KIDS) had its target price decreased by Truist Financial from $34.00 to $28.00 in a research note published on Monday morning, Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other research analysts have also commented on KIDS. JMP Securities reiterated a “market outperform” rating and issued a $50.00 price target on shares of OrthoPediatrics in a research report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Friday, September 13th.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $27.75 on Monday. The firm has a market cap of $661.25 million, a PE ratio of -28.91 and a beta of 1.17. The stock has a 50 day moving average of $28.45 and a 200 day moving average of $30.09. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03. OrthoPediatrics has a 12 month low of $23.10 and a 12 month high of $36.23.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Monday, August 5th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. OrthoPediatrics had a negative return on equity of 5.44% and a negative net margin of 14.35%. The firm had revenue of $52.80 million during the quarter, compared to the consensus estimate of $52.40 million. On average, research analysts expect that OrthoPediatrics will post -0.92 EPS for the current fiscal year.

Insider Transactions at OrthoPediatrics

In related news, General Counsel Daniel J. Gerritzen sold 10,000 shares of OrthoPediatrics stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total transaction of $293,000.00. Following the completion of the transaction, the general counsel now directly owns 77,304 shares of the company’s stock, valued at approximately $2,265,007.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 31.80% of the company’s stock.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning increased its stake in OrthoPediatrics by 15.4% in the third quarter. Creative Planning now owns 10,130 shares of the company’s stock worth $275,000 after purchasing an additional 1,353 shares during the period. SG Americas Securities LLC grew its holdings in shares of OrthoPediatrics by 113.5% in the third quarter. SG Americas Securities LLC now owns 8,199 shares of the company’s stock worth $222,000 after purchasing an additional 4,358 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of OrthoPediatrics in the second quarter worth about $203,000. AQR Capital Management LLC purchased a new position in OrthoPediatrics in the 2nd quarter worth about $223,000. Finally, Paradigm Capital Management Inc. NY lifted its holdings in OrthoPediatrics by 8.0% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 134,400 shares of the company’s stock valued at $3,865,000 after buying an additional 10,000 shares in the last quarter. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.